Price Change to Note: A Reversal for Asterias Biotherapeutics Inc Is Not Near. The Stock Declines Again

Price Change to Note: A Reversal for Asterias Biotherapeutics Inc Is Not Near. The Stock Declines Again

The stock of Asterias Biotherapeutics Inc (NYSEMKT:AST) is a huge mover today! The stock decreased 6.48% or $0.35 on November 23, hitting $5.05. About 465,111 shares traded hands or 162.36% up from the average. Asterias Biotherapeutics Inc (NYSEMKT:AST) has risen 19.95% since April 22, 2016 and is uptrending. It has outperformed by 14.54% the S&P500.
The move comes after 7 months negative chart setup for the $224.06M company. It was reported on Nov, 24 by Barchart.com. We have $4.70 PT which if reached, will make NYSEMKT:AST worth $15.68M less.

Analysts await Asterias Biotherapeutics Inc (NYSEMKT:AST) to report earnings on April, 4. They expect $-0.17 earnings per share, up 19.05% or $0.04 from last year’s $-0.21 per share. After $-0.15 actual earnings per share reported by Asterias Biotherapeutics Inc for the previous quarter, Wall Street now forecasts 13.33% negative EPS growth.

Asterias Biotherapeutics Inc (NYSEMKT:AST) Ratings Coverage

Out of 3 analysts covering Asterias Biotherapeutics (NYSEMKT:AST), 2 rate it a “Buy”, 0 “Sell”, while 1 “Hold”. This means 67% are positive. Asterias Biotherapeutics has been the topic of 4 analyst reports since August 11, 2015 according to StockzIntelligence Inc. MLV maintained Asterias Biotherapeutics Inc (NYSEMKT:AST) rating on Tuesday, August 11. MLV has “Buy” rating and $9 price target. FBR Capital initiated Asterias Biotherapeutics Inc (NYSEMKT:AST) rating on Thursday, November 19. FBR Capital has “Outperform” rating and $10 price target. Chardan Capital Markets initiated the stock with “Buy” rating in Monday, May 23 report. The stock has “Hold” rating given by Zacks on Thursday, September 3.

According to Zacks Investment Research, “Asterias Biotherapeutics, Inc. is a biotechnology company. It is focused on the field of regenerative medicine. The Company’s technologies center on stem cells capable of becoming all of the cell types in the human body, a property called pluripotency. It develops therapies based on pluripotent stem cells to treat diseases or injuries in a variety of medical fields, with an initial focus on the therapeutic areas of neurology and oncology. Asterias Biotherapeutics, Inc. is based in Menlo Park, California.”

More important recent Asterias Biotherapeutics Inc (NYSEMKT:AST) news were published by: Prnewswire.com which released: “Asterias Biotherapeutics Announces Record Date for Distribution of Warrants to …” on March 31, 2016, also Prnewswire.com published article titled: “Asterias Biotherapeutics Announces Treatment of First Spinal Cord Injury …”, Prnewswire.com published: “Asterias Biotherapeutics Announces Positive Efficacy Data in Patients with …” on September 14, 2016. More interesting news about Asterias Biotherapeutics Inc (NYSEMKT:AST) was released by: Prnewswire.com and their article: “Asterias Biotherapeutics Announces Successful End-of-Phase 2 Meeting with FDA …” with publication date: February 24, 2016.

AST Company Profile

Asterias Biotherapeutics, Inc., incorporated on October 24, 2012, is a biotechnology company. The Firm is engaged in developing and commercializing therapies in the fields of cell therapy and regenerative medicine. The Firm has over two technology platforms. The first is an immunotherapy platform to teach cancer patients’ immune systems to attack their tumors. The second is pluripotent stem cell platform. Pluripotent cells are a type of stem cell capable of becoming all of the cell types in the human body. The Firm is focused on developing therapies to treat conditions with medical needs and inadequate available therapies, with an initial focus on the therapeutic areas of oncology and neurology. From its immunotherapy platform, the Company is developing over two programs. AST-VAC1 (telomerase loaded, autologous dendritic cells), which allows patient’s own cells to recognize and fight cancer cells in acute myelogenous leukemia (AML). Together with its collaboration partner, Cancer Research United Kingdom (CRUK), it is developing AST-VAC2 (telomerase loaded, -allogeneic dendritic cells), -derived from pluripotent stem cells which could provide off the shelf cells that teaches a patient’s immune system to recognize and fight cancer cells, in non-small cell lung cancer. From its pluripotent stem cell platform, it is developing AST-OPC1, oligodendrocyte progenitor cells, in an initial clinical indication of spinal cord injury, with potential for later expansion into other neurodegenerative diseases, such as stroke and multiple sclerosis.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.

Leave a Comment